The role of the endocannabinoid system in liver diseases

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 1, 2009, Pages 65-77

  Caraceni, Paolo ^a   Domenicali, Marco ^a   Giannone, Ferdinando ^a   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CB1 receptor; CB2 receptor; chronic liver disease; cirrhosis; endocannabinoids; fatty liver; fibrogenesis; ischaemia reperfusion injury

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANTIVIRUS AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DEXANABINOL; ENDOCANNABINOID; LIPID; RIMONABANT;

ALCOHOL ABUSE; ANTIINFLAMMATORY ACTIVITY; CARDIOMYOPATHY; CELL DAMAGE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HEPATITIS C; HUMAN; INFLAMMATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER ISCHEMIA; MOLECULAR MECHANICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PROTEIN SYNTHESIS INHIBITION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ENDOCANNABINOIDS; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER DISEASES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REPERFUSION INJURY;

EID: 61649086432     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.10.009     Document Type: Review

References (69)

1. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58 (2006) 389-462
2. Mallat A., and Lotersztajn S. Endocannabinoids and liver disease. Endocannabinoids and their receptors in the liver. American Journal of Physiology. Gastrointestinal and Liver Physiology 294 (2008) G9-G12
3. Kunos G., and Osei-Hyiaman D. Endocannabinoids and liver disease. Endocannabinoid involvement in obesity and hepatic steatosis. American Journal of Physiology. Gastrointestinal and Liver Physiology 294 (2008) G1101-G1104
4. Siegmund S.V., and Schwabe R.F. Endocannabinoids and liver disease. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. American Journal of Physiology. Gastrointestinal and Liver Physiology 294 (2008) G357-G362
5. Pacher P., and Gao B. Endocannabinoids and liver disease. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. American Journal of Physiology. Gastrointestinal and Liver Physiology 294 (2008) G850-G854
6. Caraceni P., Domenicali M., and Bernardi M. The endocannabinoid system and liver diseases. Journal of Neuroendocrinology 20 Suppl. 1 (2008) 47-52
7. Sherlock S. Nutritional and metabolic liver disease. In: Sherlock S. (Ed). Disease of the liver and biliary system. 8th edn. (1989), Blackwell Scientific Publications 470-500
8. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (Baltimore, Md.) 42 (2005) 44-52
9. Ong J.P., and Younossi Z.M. Epidemiology and natural history of NAFLD and NASH. Clinics in Liver Disease 11 (2007) 1-16
10. Sampath H, Miyazaki M, Dobrzyn A, et al. Stearoyl CoA-desaturase-1 mediates the pro-lipogenic effect of dietary saturated fat. The Journal of Biological Chemistry 207(282): 2483-2493.
11. Lin J., Yang R., Tarr P.T., et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1betacoactivation of SREBP. Cell 120 (2005) 261-273
12. Osei-Hyiaman D., Depetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. The Journal of Clinical Investigation 115 (2005) 1298-1305
13. Osei-Hyiaman L.J., Zhou L., Godlewsky G., et al. The Journal of Clinical Investigation 118 (2008) 3160-3169
14. Gary-Bobo M., Elachouri G., Gallas J.F., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (Baltimore, Md.) 46 (2007) 122-129
15. Mendez-Sanchez N., Zamora-Valdes D., Pichardo-Bahena R., et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver International 27 (2006) 215-219
16. Deveaux V., Ichitogani Y., Texeira-Clerc F., et al. CB2 receptor antagonism reduces diet-induced obesity, insulin-resistance and hepatic steatosis. Hepatology (Baltimore, Md.) 46 (2007) 308A
17. Reuben A. Alcohol and the liver. Current Opinion in Gastroenterology 24 (2008) 328-338
18. Jeong W., Osei-Hyaman D., Park O., et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metabolism 7 (2008) 227-235
19. Castera L., Chouteau P., Hezode C., et al. Hepatitis C virus-induced hepatocellular steatosis. The American Journal of Gastroenterology 100 (2005) 711-715
20. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (Baltimore, Md.) 33 (2001) 1358-1364
21. Asselah T., Rubbia-Brandt L., Marcellin P., et al. Steatosis in chronic hepatitis C: why does it really matter?. Gut 55 (2006) 123-130
22. Hézode C., Roudot-Thoraval F., Zafrani E.S., et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. Journal of Viral Hepatitis 11 (2004) 455-458
23. Leandro G., Mangia A., Hui J., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130 (2006) 1636-1642
24. Charlton M.R., Pockros P.J., and Harrison S.A. Impact of obesity on treatment of chronic hepatitis C. Hepatology (Baltimore, Md.) 43 (2006) 1177-1186
25. Hézode C., Zafrani E.S., Roudot-Thoraval F., et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134 (2008) 432-439
26. Rockey D.C. Hepatic fibrosis, stellate cells, and portal hypertension. Clinics in Liver Disease 10 (2006) 459-479
27. Siegmund S.V., and Shwabe R.F. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. American Journal of Physiology. Gastrointestinal and Liver Physiology 294 (2008) G357-G362
28. Hezode C., Roudot-Thoraval F., Nguyen S., et al. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology (Baltimore, Md.) 42 (2005) 63-71
29. Teixeira-Clerc F., Julien B., Grenard P., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine 12 (2006) 671-676
30. Julien B., Grenard P., Texeira-Clerc F., et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128 (2005) 742-755
31. Siegmund S.V., Uchinami H., Osawa Y., et al. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology (Baltimore, Md.) 41 (2005) 1085-1095
32. Siegmund S.V., Qian T., De Minicis S., et al. The endocannabinoid 2-arachidonyl glycerol induces death of hepatic stellate cells via mitochondrial oxygen species. The FASEB Journal 21 (2007) 2798-2806
33. Munoz-Luque J., Ros J., Fernandez-Varo G., et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. The Journal of Pharmacology and Experimental Therapeutics 324 (2008) 475-483
34. Domenicali M., Caraceni P., Pertosa A.M., et al. Effect of cannabinoid CB1-receptor antagonism on ascitic decompensation of rats with preascitic cirrhosis. Journal of Hepatology 48 Suppl. 2 (2008) S38
35. Bosch J., Berzigotti A., Garcia-Pagan J.C., et al. The management of portal hypertension: rational basis, available treatments and future options. Journal of Hepatology 48 Suppl. 1 (2008) S68-S92
36. Yang Y.Y., Lin H.C., Huang Y.T., et al. Roles of anandamide in the hepatic microcirculation in cirrhotic rats. American Journal of Physiology. Gastrointestinal and Liver Physiology 290 (2005) G328-G334
37. Yang Y.Y., Lin H.C., Huang Y.T., et al. Effect of chronic CB1 receptor antagonism on livers of rats with biliary cirrhosis. Clinical Science 112 (2007) 533-542
38. Kowalsky H.J., and Abelmann W.H. The cardiac output at rest in Laennec's cirrhosis. The Journal of Clinical Investigation 32 (1953) 1025-1033
39. Schrier R.W., Arroyo V., Bernardi M., et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (Baltimore, Md.) 8 (1988) 1151-1157
40. Wiest R., and Groszmann R.J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology (Baltimore, Md.) 35 (2002) 478-491
41. Sacerdoti D., Abraham N.G., Oyekan A.O., et al. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. The Journal of Pharmacology and Experimental Therapeutics 308 (2004) 636-643
42. Oberti F., Sogni P., Cailmail S., et al. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology (Baltimore, Md.) 18 (1993) 621-627
43. Batkai S., Jarai Z., Wagner J.A., et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Medicine 7 (2001) 827-832
44. Ros J., Claria J., To-Figueras J., et al. A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122 (2002) 85-93
45. Maccarrone M., Bari M., Battista N., et al. Endocannabinoid degradation, endotoxic shock and inflammation. Current Drug Targets. Inflammation and Allergy 1 (2002) 53-63
46. Garcia Jr. N., Járai Z., Mirshahi F., et al. Systemic and portal hemodynamic effects of anandamide. American Journal of Physiology. Gastrointestinal and Liver Physiology 280 (2001) G14-G20
47. Ralevic V., Kendall D.A., Randall M.D., et al. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sciences 71 (2002) 2577-2594
48. Domenicali M., Ros J., Fernández-Varo G., et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 54 (2005) 522-527
49. Moezi L., Gaskari S.A., Liu H., et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. British Journal of Pharmacology 149 (2006) 898-908
50. Fernández-Rodriguez C.M., Romero J., Petros T.J., et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver International 24 (2004) 477-483
51. Lo Verme J., La Rana G., Russo R., et al. The search for the palmitoylethanolamide receptor. Life Sciences 77 (2005) 1685-1698
52. Re G., Barbero R., Miolo A., et al. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Veterinary Journal (London, England : 1997) 173 (2007) 21-30
53. Gaskari S.A., Honar H., and Lee S.S. Therapy insight: cirrhotic cardiomyopathy. Nature Clinical Practice. Gastroenterology & Hepatology 3 (2006) 329-337
54. Zambruni A., Trevisani F., Caraceni P., et al. Cardiac electrophysiological abnormalities in patients with cirrhosis. Journal of Hepatology 44 (2006) 994-1002
55. Gaskari S.E., Liu H., Moezi L., et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. British Journal of Pharmacology 146 (2005) 315-323
56. Batkai S., Mukhopadhyay P., Harvey-White J., et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. American Journal of Physiology. Heart and Circulatory Physiology 293 (2007) H1689-H1695
57. Huguet C., Gavelli A., Chieco A., et al. Liver ischemia for hepatic resection: where is the limit?. Surgery 111 (1992) 251-259
58. Selzner M., and Clavien P.A. Fatty liver in liver transplantation and surgery. Seminars in Liver Disease 21 (2001) 105-113
59. Strasberg S.M., Howard T.K., Molmenti E.P., et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology (Baltimore, Md.) 20 (1994) 829-838
60. Jaeschke H. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. American Journal of Physiology. Gastrointestinal and Liver Physiology 290 (2006) G1083-G1088
61. Kurabayashi M., Takeyoshi I., Yoshinari D., et al. 2-arachidonylglycerol increases in ischemia-reperfusion injury of rat liver. Journal of Investigative Surgery 18 (2005) 25-31
62. Batkai S., Osei-Hyiaman D., Pan H., et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia-reperfusion injury. The FASEB Journal 21 (2007) 1781-2000
63. Rajesh M., Pan H., Mukhopadhyay P., et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia-reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. Journal of Leukocyte Biology 82 (2007) 1382-1389
64. Pacher P., and Hasko G. Endocannabinoids and cannabinoid receptors in ischemia-reperfusion injury and preconditioning. British Journal of Pharmacology 153 (2008) 252-262
65. Marshall J.C., and Nathens A.B. The gut in critical illness: evidence from human studies. Shock 6 (1996) S10-S16
66. Colletti L.M., and Green M. Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous lipopolysaccaride which also increases hepatic TNF production in vivo and in vitro. Shock (Augusta, Ga.) 16 (2001) 312-319
67. Kojima Y., Suzuki S., Tsuchiya Y., et al. Regulation of pro-inflammatory and anti-inflammatory cytokine responses by Kupffer cells in endotoxin-enhanced reperfusion injury after total hepatic ischemia. Transplant International 16 (2003) 231-240
68. Jaeschke H., and Bajt M.L. Critical role of CXC chemokines in endotoxemic liver injury in mice. Journal of Leukocyte Biology 76 (2004) 1089-1090
69. Di Marzo V. targeting the endocannabinoid system: to enhance or reduce?. Nature Reviews. Drug Discovery 7 (2008) 438-455